RCM Technologies (RCMT) Q1 2025 earnings summary

Executive summary

• Revenue rose 17.4% year-over-year to $84.5 million for Q1 2025, driven by strong growth in Engineering and Specialty Health Care segments, with all business units reporting robust pipelines and new client wins.

• Net income increased to $4.2 million ($0.54 per diluted share) from $4.0 million ($0.48) in Q1 2024, and adjusted EPS rose to $0.63.

• Operating income grew to $6.6 million, up from $5.8 million year-over-year, reflecting higher gross profit despite increased SGA expenses.

• Strong cash flow from operations of $16.7 million enabled $12.0 million net debt reduction and share repurchases.

• Leadership development, succession planning, and a focused investment strategy are emphasized for long-term success.

Financial highlights

• Q1 2025 consolidated gross profit was $22.0 million, up 7.9% year-over-year, with gross margin at 26.0% (down from 28.3%).

• Adjusted EBITDA grew 14.4% to $7.8 million, and adjusted EBITDA margin was 9.2%.

• Diluted weighted average shares outstanding: 7.74 million (down from 8.17 million year-over-year).

• SGA expenses rose to $15.0 million but decreased as a percentage of revenue to 17.7%.

• Effective tax rate increased to 28.9% from 26.9%.

Outlook and guidance

• Expectation for continued low double-digit adjusted EBITDA growth throughout fiscal 2025, with Q4 2025 anticipated to be the strongest quarter.

• Management expects to maintain compliance with financial covenants and sufficient liquidity for at least the next 12 months.

• Strategic focus remains on internal growth, selective acquisitions, and targeted verticals.